KOSDAQBiotech & Pharma220100

FutureChem

₩7,170▲ 1.41%2026-10-02 close

Market Cap

₩185.6B

Turnover

₩500M

Volume

60,000 shares

Shares out.

25.8M

PER

—

PBR

—

EPS

—

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Diagnostic Sales Growth vs. Therapeutic Trial Cost Burden

FutureChem, a Korean radiopharmaceutical (theranostics) specialist, has posted four straight years of revenue growth from diagnostic sales while continuing to post losses amid expanding clinical costs, with the FC705 and FC303 approval and licensing timelines seen as pivotal for future earnings.

1
Annual revenue rose for four consecutive years from KRW 12.57bn in 2022 to KRW 18.67bn in 2025, but the company still posted an operating loss of KRW 7.75bn in 2025.
2
The prostate cancer diagnostic FC303 (Prostavue) received domestic marketing approval in May 2026, becoming the company's third commercialized diagnostic new drug after AlzaVue and PDVue.
3
The prostate cancer therapeutic FC705 began domestic Phase 3 trials in February 2026, and dosing in the US Phase 2a trial has been completed, with the clinical study report (CSR) expected in the fourth quarter of 2026.
4
A KRW 40bn rights offering announced in June 2026 secured funding for FC705 trials and commercialization, but it could act as a future dilution factor.
5
Domestic rival Cellbion filed for conditional approval of its therapeutic candidate first, intensifying competition to secure an early lead in the domestic market.

Business structure

Founded in 2001 as a manufacturer of radiopharmaceutical precursors, FutureChem is a radioligand drug specialist that transferred its listing to KOSDAQ in 2016.

The business spans three areas: development, production and sales of radiopharmaceutical new drugs; production and sales of precursors and synthesis reagents; and sales of automated synthesis devices.

Most revenue comes from radiopharmaceutical sales, with the Alzheimer's diagnostic AlzaVue and Parkinson's diagnostic PDVue forming the existing commercial lineup.

In May 2026 the prostate cancer diagnostic FC303 (Prostavue) received Korean regulatory approval, completing a diagnostic portfolio spanning lung cancer, Parkinson's disease, Alzheimer's disease and prostate cancer.

On the therapeutics side, FC705, which combines lutetium-177 with a PSMA-targeting peptide, is being developed for metastatic castration-resistant prostate cancer (mCRPC) through parallel domestic Phase 3 and US Phase 2a trials.

Subsidiaries include FutureChem Healthcare, SI Healthcare and FutureChem U.S.A., with the US entity supporting global clinical and commercialization efforts.

The domestic radiopharmaceutical market is structured around four players—FutureChem, Cellbion, DuChem Bio and SK Biopharmaceuticals—with FutureChem and Cellbion focused on therapeutics while DuChem Bio emphasizes manufacturing and distribution infrastructure.

Overseas, the company has signed a supply agreement with Indonesia and is reportedly negotiating further supply deals across Southeast Asia, Europe, Latin America and the Middle East.

Earnings trend

Quarterly revenue · Operating profit

₩3.6B-₩1.9B25Q2₩3.8B-₩2.5B25Q3₩6.2B-₩1.4B25Q4₩6.4B-₩2.2B26Q1₩4.3B-₩3.2B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩12.6B-₩12.9B2022₩14B-₩8.4B2023₩17.3B-₩9.5B2024₩18.7B-₩7.8B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩3.6B	-₩1.9B	−52.6%
2025Q3	₩3.8B	-₩2.5B	−66.7%
2025Q4	₩6.2B	-₩1.4B	−22.9%
2026Q1	₩6.4B	-₩2.2B	−34.8%
2026Q2	₩4.3B	-₩3.2B	−75.4%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩12.6B	-₩12.9B	-₩14B	−102.9%	−19.9%	26.2%
2023	₩14B	-₩8.4B	-₩6.7B	−60.2%	−10.5%	14.0%
2024	₩17.3B	-₩9.5B	-₩9.4B	−54.7%	−17.3%	36.5%
2025	₩18.7B	-₩7.8B	-₩11.3B	−41.5%	−20.6%	35.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21

Earnings analysis

Annual revenue rose consecutively from KRW 12.57bn in 2022 to KRW 13.97bn in 2023, KRW 17.29bn in 2024 and KRW 18.67bn in 2025.

Over the same period, operating losses fluctuated from KRW 12.93bn to KRW 8.41bn, KRW 9.47bn and KRW 7.75bn, with 2025 showing a narrower loss than the prior year and an improving operating trend.

However, net loss attributable to owners actually widened from KRW 6.71bn in 2023 to KRW 9.42bn in 2024 and KRW 11.25bn in 2025, diverging from the narrower operating loss.

On a quarterly basis, the fourth quarter of 2025 alone posted a net loss of KRW 7.57bn, the primary driver of the full-year net loss expansion, which appears to reflect non-operating factors such as clinical or R&D-related cost recognition or asset revaluation.

By contrast, in the second quarter of 2025 and the second quarter of 2026, despite operating losses of KRW 1.92bn and KRW 3.22bn respectively, net income attributable to owners turned positive at KRW 2.59bn and KRW 2.31bn, illustrating how non-operating swings can significantly move quarterly results.

First-half 2026 revenue reached KRW 10.63bn, up 22.0% year-on-year, though the operating loss also widened over the same period. Operating cash flow has shown a narrowing deficit trend, moving from -KRW 7.61bn in 2022 to -KRW 3.72bn in 2023, -KRW 3.21bn in 2024 and -KRW 2.43bn in 2025.

Owners' equity declined from KRW 70.14bn in 2022 to KRW 54.65bn in 2025, but ticked up slightly from KRW 54.38bn in 2024, suggesting the capital base has been sustained through external funding despite ongoing net losses.

Industry analysis

The global radiopharmaceutical therapy (RPT) market is led by Novartis' prostate cancer treatment Pluvicto, which reportedly generated about $980 million (roughly KRW 1.4 trillion) in revenue in 2023.

The related market is projected to grow from roughly KRW 2.7 trillion in 2024 to about KRW 20 trillion by 2032 at a double-digit annual growth rate.

In Korea, Cellbion and FutureChem are competing as challengers chasing Pluvicto, with Cellbion having filed for domestic conditional approval of its therapeutic 177Lu-DGUL (Pocuvotide) and reportedly set to begin trials with global pharmaceutical company Merck in the second half.

FutureChem, meanwhile, is relatively ahead in US trials, positioning its access to Western patient data as a strength in future licensing negotiations.

Global big pharma interest in radiopharmaceuticals is also evidenced by Bristol Myers Squibb's roughly $4.1 billion licensing deal involving RayzeBio's pipeline candidates.

Radiopharmaceuticals require specialized production and distribution infrastructure due to short half-lives, which serves as both an entry barrier and a supply-chain risk factor.

The domestic industry structure shows a division of roles between therapeutic development (FutureChem, Cellbion), manufacturing and distribution (DuChem Bio), and later entry (SK Biopharmaceuticals).

Outlook

FutureChem began dosing the first patient in FC705's domestic Phase 3 trial at Seoul St. Mary's Hospital in February 2026, stating it plans to obtain topline Phase 3 results as early as the following year.

In the US, patient dosing for FC705's Phase 2a trial has been completed, with a clinical study report expected in the fourth quarter of 2026, which the company expects will accelerate licensing discussions with global pharmaceutical partners.

On the diagnostics side, following FC303's domestic approval in May, the company stated it has completed a Phase 3 trial in China and plans to file for marketing approval with Chinese regulators.

The company said it expects continued revenue growth as it prepares for FC303's market launch, and stated that the value of both FC303 and FC705 would become more visible starting in the second half.

In June 2026 the company disclosed a KRW 40 billion rights offering to fund domestic and overseas FC705 trials and commercialization preparation, explaining the proceeds would go toward the domestic Phase 3 trial, indication expansion, and partnership and marketing costs for US market entry.

Overseas diagnostic supply is reportedly being expanded beyond the initial Indonesia agreement into Southeast Asia, Europe, Latin America and the Middle East.

Valuation

PER

—

PBR

—

ROE

-20.4%

EPS

—

BPS

—

Dividend per share

₩0

The current share price trades well above book value per share, placing it in a range that reflects a premium to net assets.

With net losses persisting, valuation has tended to rely more on asset- and sales-based metrics than earnings-based ones, and the price-to-book ratio has reportedly ranged broadly from roughly 2 times to 12 times over the past five years.

The company has no recent dividend payment history based on available data, so a dividend-yield framing does not apply. While net losses have widened since 2023, revenue has grown for four consecutive years, leaving top-line and bottom-line trends pointing in different directions.

Should FC705 and FC303 commercialization outcomes become clearer going forward, the interpretive framework for these asset- and sales-based metrics could shift.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21

Bull factors

Expanding Commercialization of Diagnostic Portfolio

FC303 received domestic marketing approval in May 2026, becoming the third diagnostic new drug to reach the commercialization stage after AlzaVue and PDVue.

Following a supply agreement with Indonesia, the company is reportedly negotiating further supply deals across Southeast Asia, Europe, Latin America and the Middle East, suggesting potential geographic diversification of diagnostic revenue.

Completion of a Phase 3 trial in China and preparation for a local approval filing also point to a possible additional revenue source.

FC705 Differentiation and Licensing Potential

FC705 recorded an objective response rate (ORR) of 60% and disease control rate (DCR) of 93.3% in domestic Phase 2 trials, and is being developed with a best-in-class goal.

The company has stated that securing Western patient data through the US trial could be a strength in future licensing negotiations with global pharmaceutical companies.

Bristol Myers Squibb's roughly $4.1 billion licensing deal for RayzeBio's radiopharmaceutical candidates illustrates the potential scale of deals in this space.

Revenue Growth and Narrowing Cash Burn

Annual revenue grew for four consecutive years from KRW 12.57bn in 2022 to KRW 18.67bn in 2025. The operating cash flow deficit has also narrowed each year, from KRW 7.61bn in 2022 to KRW 2.43bn in 2025. This suggests that growth in existing diagnostic product sales has contributed in part to improving cash flow.

Bear factors

Continued Losses and Widening Net Loss

The operating loss reached KRW 7.75bn in 2025, marking a fourth consecutive year of losses. Net loss attributable to owners actually widened from KRW 6.71bn in 2023 to KRW 11.25bn in 2025, showing that revenue growth has not translated directly into improved earnings. In the first half of 2026, revenue grew but the operating loss also widened.

Concerns Over Trailing Position in Domestic Therapeutics Race

Domestic rival Cellbion has filed for conditional approval of its therapeutic 177Lu-DGUL first, appearing to lead in securing an early position in the domestic market.

Cellbion is reportedly set to begin trials with global pharmaceutical company Merck in the second half, which could invite comparisons in domestic and international partnership competition. However, FutureChem's relatively more advanced progress in US trials stands as a counterbalancing factor.

Funding and Dilution Burden

In June 2026, the company disclosed a KRW 40 billion rights offering to fund FC705 clinical and commercialization needs. Given ongoing net losses and clinical cost burdens, the need for further external financing may persist going forward. Repeated capital raises could continue to have a dilutive effect on per-share metrics.

Risk factors

Clinical and Regulatory Risk

FC705's domestic Phase 3 trial and conditional approval, as well as the US Phase 2a CSR results, remain unresolved matters that could face schedule delays or results falling short of expectations. FC303's China approval filing could also see its progress vary depending on the review outcome from local regulators.

It is also worth noting that radiopharmaceuticals can be subject to disputes over interpretation differences in clinical design and evaluation criteria such as RECIST or mPERCIST.

Competitive and Technology Risk

In the global market, Novartis' Pluvicto has already succeeded commercially and holds a dominant position. Domestically, Cellbion is ahead in filing for conditional approval and has a known collaboration plan with Merck, intensifying competition.

If licensing negotiations are delayed or unfold more favorably for competitors, FutureChem's relative position could weaken.

Financial and Operational Risk

As net loss attributable to owners widened to KRW 11.25bn in 2025, the need for capital raising has persisted.

Because radiopharmaceuticals have short half-lives, they require specialized production and distribution infrastructure and logistics management, and supply chain disruptions could affect both revenue and clinical timelines.

The debt ratio has also risen from 14.0% in 2023 to 35.9% in 2025, making the change in financial structure worth monitoring.

What to watch next

Around November 2026
The third-quarter 2026 quarterly report disclosure should be checked for revenue and operating loss trends, as well as the status of rights offering fund usage.
During the fourth quarter of 2026
Whether FutureChem receives and discloses the clinical study report (CSR) for FC705's US Phase 2a trial should be checked, as this could serve as supporting data for future global licensing discussions.
From the second half of 2026 onward
The progress of FC303's marketing approval filing in China and whether additional supply agreements are signed beyond Indonesia (Southeast Asia, Europe, Latin America, Middle East) should be checked.
During 2027
Whether and when the company delivers the topline results of FC705's domestic Phase 3 trial, as previously indicated by the company, should be checked.

Overall view

FutureChem is broadening its commercialization base through steady growth in existing diagnostic sales and the domestic approval of FC303, but it continues to show a dual structure of persistent operating and net losses driven by clinical and R&D cost burdens.

Its core growth driver, the therapeutic FC705, is undergoing simultaneous domestic Phase 3 and US Phase 2a trials, with the US CSR results expected in the fourth quarter of 2026 and any future push for domestic conditional approval standing as key items to watch.

In the domestic market, Cellbion's lead in filing for conditional approval is sharpening the competitive landscape, a variable that could affect FutureChem's relative position.

The KRW 40 billion rights offering is a double-edged development, securing funding for trials and commercialization while potentially adding to future per-share dilution.

While revenue has grown for four consecutive years, net losses have actually widened, making how diagnostic sales expansion and therapeutic clinical outcomes reshape the earnings structure the central point to monitor going forward.

This report does not include an investment opinion or a buy/sell recommendation and is intended for informational purposes only.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.